Psychosis

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

September 18, 2018

A report from the Department of Health and Human Services (HHS) found that 1 in 3 foster children sampled in 5 states received the drugs without treatment plans or follow-up.

Treating Older Adult Bipolar Disorder: Newer Atypical Antipsychotics Compared

By September 10, 2018

While pharmacologic agents such as lithium and valproic acid have been shown to provide significant antimanic effects in older adults with bipolar disorder, an increase in the use of atypical antipsychotics in the general adult bipolar population prompted researchers to investigate the efficacy and tolerability of these agents in OABD.

Most Antipsychotics Prescribed in Nursing Homes Initiated There

August 09, 2018

The researchers found that 64% of study participants had new antipsychotic use initiated in nursing homes, 18.6% had initiation in hospitals, and 17.5% had initiation in outpatient settings.

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

By July 30, 2018

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Off-Label Prescribing Common With Certain Psychiatric Medications

By July 26, 2018

Using data from the 2012 and 2013 National Ambulatory Medical Care Surveys, researchers looked at all adult outpatient visits to psychiatric practices for chronic care management in which ≥1 psychiatric medication was prescribed.

Blister Packs for Several Meds Recalled Due to Risk of Harm to Children

By July 09, 2018

The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.

Atypical Antipsychotic Use and CV Events in Youth: What's the Link?

By July 06, 2018

The retrospective cohort study involved a search of Medicaid claims of pediatric patients aged 5 to 20 years who were initiated on atypical antipsychotic medications.

Aristada Initio Regimen Approved for Initiation of Schizophrenia Treatment

By July 02, 2018

Prior to this approval, the Aristada initiation regimen consisted of taking oral aripiprazole for 21 consecutive days starting with the first Aristada dose.

FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Cannabis Use Linked to Psychosis Symptoms in Adolescents

June 19, 2018

These correlations were similar in size to the autoregressive link between PS from ages 15 to 16. There was a statistically significant association for PS at age 15 years with cannabis use at age 16 years.

AMA President Calls Physicians to Lead in Addressing Gun Violence

June 14, 2018

For decades the AMA has demonstrated leadership on this issue, recommending common-sense gun safety precautions, waiting periods and background checks for those wishing to purchase a gun, and increased mental health service funding.

Tobacco Cessation Support Lacking in Mental Health Facilities

May 14, 2018

The researchers found that 48.9% of mental health treatment facilities reported screening patients for tobacco use in 2016; 37.6, 25.2, and 21.5% offered tobacco cessation counseling, nicotine replacement therapy, and non-nicotine tobacco cessation medications, respectively.

Antipsychotic Use and Gestational Diabetes: Is There a Link?

By May 08, 2018

Results showed there was a significant crude risk linked to continuing vs discontinuing certain antipsychotics and developing gestational diabetes; for quetiapine the risk was 7.1% vs 4.1% (adjusted relative risk [ARR] 1.28), respectively; among olanzapine users it was 12% vs 4.7% (ARR 1.61), respectively.

Risk of Pediatric Mental Illness Up After Injury Hospitalization

May 08, 2018

Post-injury, children ages 0 to 4 years with burns were more likely to have mental health diagnoses, after adjustment for race and ethnicity.

Early Intervention Services Best for Early-Phase Psychosis

May 07, 2018

"In early-phase psychosis, EIS are superior to TAU across all meta-analyzable outcomes," the authors write. "These results support the need for funding and use of EIS in patients with early-phase psychosis."

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson's Disease Patients

By April 27, 2018

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Substance Use Disorders Linked to Conversion to Schizophrenia

April 26, 2018

This prospective cohort study included a population-based sample of 2,539 individuals born in Denmark with an incident diagnosis of schizotypal disorder and without a previous diagnosis of schizophrenia.

Politically-Focused Thoughts, Behaviors Tied to Psychopathology

April 13, 2018

"The findings suggest that politically-focused intrusive thoughts and ritualistic behaviors are associated with psychopathology domains in a manner comparable to general obsessive-compulsive symptoms," the authors write.

Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids

By April 12, 2018

Iatrogenic steroid-induced psychosis is a rare side effect of glucocorticoid therapy which is mostly seen in adults, although it has been reported in children and adolescents.

Parent-Child Book Reading Tied to Psychosocial Benefits

March 29, 2018

The researchers found that PCBR interventions improved the psychosocial functioning of children and parents compared with controls (standardized mean difference, 0.185).

Pimavanserin Evaluated in Patients With Alzheimer's Disease Psychosis

February 15, 2018

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.

Virtual Reality-Based CBT May Benefit Patients With Psychotic Disorders

February 12, 2018

VR-CBT in addition to standard treatment can reduce paranoid ideation, momentary anxiety

Are Psychiatric Drugs Being Overprescribed in Children and Adolescents?

By January 30, 2018

"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.

Specific White Matter Patterns Linked to Youth Psychopathology

January 29, 2018

The feature most associated with both of these traits was a brain white matter pattern reflecting frontotemporal connectivity and crossing fibers in the uncinate fasciculus.

Teen Cannabis Use Linked to Subsequent Psychotic Experiences

January 19, 2018

Risk also increased with early-onset cigarette-only use, but correlation attenuated after adjustment

Number of Adults Seeking Mental Health Specialty Care Increasing

January 12, 2018

The researchers found that between 2008 to 2009 and 2014 to 2015 the number of U.S. adults who received specialty outpatient mental health care rose from 11.3 million to 13.7 million per year/

Is AVATAR Therapy a Viable Treatment for Auditory Hallucinations?

November 27, 2017

The researchers found that 83% of participants met the primary outcome of reduction in auditory verbal hallucinations at 12 weeks, as measured by the total score on the Psychotic Symptoms Rating Scales Auditory Hallucinations (PSYRATS-AH).

FDA Grants Fast Track Status to Lumateperone for Schizophrenia

By November 20, 2017

In two studies, lumateperone showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score.

FDA Approves Antipsychotic Agent With Sensor to Track Ingestion

By November 14, 2017

The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.

Long-Term Effects of Valbenazine Examined in Adults With Tardive Dyskinesia

By November 14, 2017

Maintenance of treatment effect was demonstrated with both doses.